By Maureen Martino Sanofi-Aventis is considering four deals for eye-drug for a total of €1 billion ($1.36 billion) in possible acquisitions, French newspaper Les Echos reports. Three of the potential deals are for ophthalmology assets based in the U.S., while the fourth is in Israel. “The sum would be spread over three years, as the transactions …
By John Carroll Sanofi execs are guiding analysts today on its progress with new diabetes and cancer drugs, but most of their guests are likely to be more focused on the painstakingly slow progress of the pharma giant’s bid to acquire Genzyme. Dow Jones reported yesterday afternoon that Sanofi’s board will gather in coming days to …
By John Carroll Genzyme (GENZ) is in play. After days of fevered speculation over what Genzyme would be worth to a company like Sanofi-Aventis, the big pharma outfit appears to have set its sights on the low side of the spectrum. According to a flurry of news reports, Sanofi CEO Chris Viehbacher and the board think …
By Tracey Staton Sanofi-Aventis (NYSE: SNY) has plenty of potential competition in a bid for Genzyme (NASDAQ: GENZ). Big Pharma has been stepping up its interest in rare diseases, which Genzyme treats with several lucrative drugs. And there’s not a major drugmaker out there that doesn’t need new revenues to help offset impending generic competition for …
By John Carroll Genzyme (NASDAQ: GENZ) isn’t letting a little manufacturing crisis get in the way of its ambitious long-term growth plans. The big biotech outfit has blueprinted a massive 757,000-square-foot expansion at its Framingham, MA facility, with some 400,000 square feet of new space reserved for its research operations. The Boston Globe reports that state officials are …
